Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAROCAINE: Intra-parotid bupivacaine + dexamethasone after partial parotidectomy
2025-524358-32-00Phase 2Authorised
- Sponsor
- CHU Nîmes
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bupivacaine and dexamethasone in Benign Parotid Neoplasm, sponsored by CHU Nîmes. Primary endpoint: Local side effects within 15 days. Planned start Mar 2026; status: authorised.
02
Drugs
bupivacainedexamethasone
03
Conditions
Benign Parotid Neoplasm
Beyond the preview
Go deeper on 2025-524358-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524358-32-00.